...
首页> 外文期刊>Clinical and experimental ophthalmology >Subthreshold transpupillary thermotherapy in Chinese patients with myopic choroidal neovascularization: one- and two-year follow up.
【24h】

Subthreshold transpupillary thermotherapy in Chinese patients with myopic choroidal neovascularization: one- and two-year follow up.

机译:中国近视脉络膜新生血管患者的阈下经瞳孔热疗:一年和两年的随访。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: To perform a safety and efficacy study of subthreshold transpupillary thermotherapy (TTT) in Chinese patients with choroidal neovascularization (CNV) secondary to pathologic myopia. METHODS: In a prospective study, patients with subfoveal or juxtafoveal CNV secondary to high myopia underwent subthreholdTTT with fixed treatment and follow-up protocols. From October 2002 to July 2005, 12 and 24 months of follow up were completed for 21 eyes and 13 eyes respectively. RESULTS: The mean best-corrected visual acuities (BCVA) were maintained at the baseline level at 1 and 2 years. Seventy-two per cent of eyes and 63% of eyes had stable or improved BCVA at 12 and 24 months.Thirty-four per cent and 39% of eyes had a moderate gain in vision (improved by three or more lines) at 12 and 24 months respectively.The average number of subthreshold TTT treatments was 1.7. The major complication of subthresholdTTT included laserrelated low-grade retinal pigment epithelium atrophy in two eyes of young patientswith clear lenses. The final VA was significantly associated with pretreated VA (r = 0.614, P = 0.003).The final VA improvement was significantly associated with pretreatment VA in negative correlation (r=-0.731, P = 0.0002, Person correlation test). CONCLUSIONS: Subthreshold TTT in Chinese patients with pathologic myopia and subfoveal or juxtafoveal CNV generally maintained vision at 1- and 2-year follow up. Using decreased power of subthreshold TTT, especially in the younger patients with a clear lens, is suggested.
机译:摘要背景:对中国继发于病理性近视的脉络膜新生血管(CNV)患者进行阈下经瞳孔热疗(TTT)的安全性和有效性研究。方法:在一项前瞻性研究中,对高度近视继发于中央凹或近中央凹的CNV患者进行了阈下TTT固定治疗和随访方案。从2002年10月至2005年7月,分别完成了21眼和13眼的12个月和24个月的随访。结果:平均最佳矫正视力(BCVA)维持在基线水平1年和2年。在12和24个月时,BCVA稳定或改善了72%的眼睛和63%的眼睛;在12和24个月时,分别有34%和39%的眼睛有中等程度的视力(改善了三行或更多行)。分别为24个月。平均阈下治疗次数为1.7。阈下TTT的主要并发症包括年轻患者的两只透明镜患者的眼睛中与激光有关的低度视网膜色素上皮萎缩。最终的VA与预处理的VA显着相关(r = 0.614,P = 0.003)。最终的VA改善与预处理的VA呈负相关(r = -0.731,P = 0.0002,人员相关性检验)。结论:中国病理性近视和小凹或近中凹CNV患者的阈下TTT一般在1年和2年随访中保持视力。建议降低阈值下阈值TTT的功效,尤其是在年轻的晶状体透明患者中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号